8-K: Tempest Therapeutics Implements 1-for-13 Reverse Stock Split

Tempest Therapeutics enacts a 1-for-13 reverse stock split to increase its stock price and maintain Nasdaq compliance.

Summary

• Tempest Therapeutics, Inc. filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-13 reverse stock split.
• The reverse stock split was authorized by stockholders at a special meeting on December 3, 2024.
• Effective at 5:00 p.m. Eastern Time on April 8, 2025, every 13 shares of common stock will be converted into one share.
• Proportionate adjustments will be made to stock options, warrants, and shares reserved under equity incentive plans.
• No fractional shares will be issued; stockholders will receive cash payments instead.
• The reverse stock split will not affect stockholders' percentage ownership, except for fractional shares.
• The common stock will begin trading on a split-adjusted basis on April 9, 2025, under the new CUSIP number 87978U207.
• As of April 4, 2025, there were 45,764,184 shares outstanding; after the split, there will be approximately 3,520,321 shares outstanding.

Sentiment

Score: 5

Explanation: The sentiment is neutral. A reverse stock split is a financial maneuver, not necessarily indicative of positive or negative long-term prospects. Its success depends on the company's subsequent performance.

Positives

• The reverse stock split aims to increase the market price of the company's common stock.
• The reverse split will help the company maintain its listing on the Nasdaq Capital Market.
• Stockholders' percentage ownership will remain the same, except for minor adjustments related to fractional shares.

Negatives

• The reverse stock split reduces the number of outstanding shares, which could be perceived negatively by some investors.
• Stockholders holding fractional shares will receive cash instead, potentially diluting their investment slightly.

Risks

• The reverse stock split may not be effective in increasing the stock price if the underlying business fundamentals do not improve.
• There is a risk of negative market perception associated with reverse stock splits.

Future Outlook

The company expects the reverse stock split to help maintain its Nasdaq listing and potentially improve its stock price.

Industry Context

Reverse stock splits are often used by companies facing delisting from major exchanges due to low stock prices. It's a common strategy to regain compliance with minimum price requirements.

Comparison to Industry Standards

• Many biotech companies with promising but yet-to-be-commercialized therapies have used reverse stock splits to maintain exchange listings.
• For example, companies like Geron Corporation and BioTime have previously implemented reverse stock splits to meet Nasdaq's minimum bid price requirement.
• The success of a reverse stock split depends on the company's ability to improve its financial performance and investor confidence following the split.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain largely the same.
• Employees holding stock options or warrants will see adjustments to the exercise price and number of shares.
• The company hopes to maintain its Nasdaq listing, which benefits all stakeholders.

Next Steps

• The company will implement the reverse stock split on April 8, 2025.
• The company's common stock will begin trading on a split-adjusted basis on April 9, 2025.
• Stockholders holding physical certificates will need to surrender them to receive new certificates or cash for fractional shares.

Key Dates

Keywords

reverse stock split, Tempest Therapeutics, common stock, stockholders, Nasdaq, Charter Amendment